Apremilast Add-On Benefits Over Conventional Drugs (ABCD) in Unstable Non-segmental Vitiligo: A 12-Week Single-Center Randomized Controlled Trial.

Sharma, Sakshi; Bhardwaj, Abhishek; Dwivedi, Pradeep; Yadav, Suraj Singh; Shamim, Muhammad Aaqib; Singh, Surjit; Sharma, Prem Prakash; Ambwani, Sneha; SIngh, Kuldeep

Sharma, Sakshi; Bhardwaj, Abhishek; Dwivedi, Pradeep; Yadav, Suraj Singh; Shamim, Muhammad Aaqib; Singh, Surjit; Sharma, Prem Prakash; Ambwani, Sneha; SIngh, Kuldeep.

Afiliação

Sharma S; Pharmacology, All India Institute of Medical Sciences, Jodhpur, IND.
Bhardwaj A; Dermatology, All India Institute of Medical Sciences, Jodhpur, IND.
Dwivedi P; Pharmacology, All India Institute of Medical Sciences, Jodhpur, IND.
Yadav SS; Pediatrics, All India Institute of Medical Sciences, Jodhpur, IND.
Shamim MA; Pharmacology, All India Institute of Medical Sciences, Jodhpur, IND.
Singh S; Pharmacology, All India Institute of Medical Sciences, Jodhpur, IND.
Sharma PP; Community and Family Medicine, All India Institute of Medical Sciences, Jodhpur, IND.
Ambwani S; Pharmacology, All India Institute of Medical Sciences, Jodhpur, IND.
SIngh K; Pediatrics, All India Institute of Medical Sciences, Jodhpur, IND.

Cureus ; 15(4): e37180, 2023 Apr.

Article em En | MEDLINE | ID: mdl-37153322

Palavras-chave

apremilast; autoimmune diseases; bsa; dlqi; non-segmental vitiligo; phosphodiesterase 4 inhibitors; unstable vitiligo; vasi

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2023 Tipo de documento: Article